CD24Fc Modulation of Siglec Receptors for NASH Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for non-alcoholic steatohepatitis (NASH) are ineffective, and the molecular interactions underlying chronic inflammation in metabolic syndromes remain poorly understood, leading to a lack of effective therapeutic approaches for this aggressive form of liver disease.
Innovation Solution
Administration of CD24 protein or Siglec agonists to target CD24-Siglec interactions, which suppress inflammation and metabolic disorders by reducing hepatomegaly, steatosis, and liver fibrosis, thereby addressing the underlying inflammatory pathways in NASH.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for NASH, then current therapeutic approaches are applied, but they are ineffective in treating the disease
Solution Approach 1:
The patent introduces CD24Fc as an intermediary molecule that binds to Siglec receptors on immune cells, thereby mediating the suppression of inflammation and immune cell infiltration in NASH. This intermediary approach provides a novel therapeutic mechanism that overcomes the ineffectiveness of conventional treatments by targeting the underlying inflammatory pathways through a specific molecular interaction between CD24Fc and Siglec.
2Loss of information
If the molecular interactions underlying chronic inflammation are not understood, then therapeutic development is hindered, but understanding these interactions requires extensive research
Solution Approach 1:
The patent performs preliminary action by identifying and characterizing the CD24-Siglec molecular interaction pathway before developing therapeutic applications. The inventors conducted extensive preclinical studies to establish the role of CD24Fc in suppressing inflammation and reducing liver fibrosis, thereby creating a foundation of knowledge that accelerates subsequent therapeutic development and reduces the time required for translating molecular understanding into clinical treatments.
3Object-affected harmful factors
If CD24Fc treatment is administered, then steatosis and inflammation are reduced, but the mechanism of action involves complex immune modulation
Solution Approach 1:
The patent extracts the harmful inflammatory component from the complex immune system by specifically targeting the CD24-Siglec interaction pathway. CD24Fc selectively binds to Siglec receptors on inflammatory immune cells, extracting and suppressing the harmful inflammatory response while leaving other immune functions intact. This extraction approach simplifies the therapeutic mechanism by focusing on a specific molecular interaction rather than attempting to modulate the entire immune system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
CD24Fc treatment significantly alleviates steatosis, inflammation, and liver fibrosis, demonstrating its potential as a therapeutic approach for preventing and treating NASH by modulating key inflammatory cytokines and improving metabolic homeostasis.
Implementation Method 1
CD24 is a cell surface glycoprotein rich in sialic acid. It has been demonstrated that CD24 interacts with members of the Siglec family of proteins to suppress inflammation caused by tissue injuries
Data Source
AI summary
Provided herein are methods and compositions for the prevention and treatment of nonalcoholic steatohepatitis (NASH) by targeting the CD24-Siglec axis.